Anna Blobaum
-
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read MoreAug 7, 2017